NMPA Approves ORPATHYS® for MET-Amplified Gastric Cancer in China
HCM is trading near its 52-week low of $9.77 (10% above the low) on elevated volume (2.1× avg).
Summary
HUTCHMED received NMPA approval in China for ORPATHYS® (savolitinib) to treat MET-amplified advanced gastric cancer, marking a significant expansion of the drug's indications and addressing a critical unmet medical need.
Key Events · Product Development and Regulatory · HCM
-
NMPA Approval for ORPATHYS®
The China National Medical Products Administration (NMPA) granted conditional approval for ORPATHYS® (savolitinib) for locally advanced or metastatic gastric cancer or gastroesophageal junction adenocarcinoma patients with MET amplification who have failed at least two prior systemic treatments.
-
First Selective MET Inhibitor
ORPATHYS® is the first selective MET inhibitor approved for this specific indication in China, addressing a significant unmet medical need for patients with MET-amplified gastric cancer.
-
Expanded Indication
This marks the third approved indication for ORPATHYS® in China, further broadening its commercial reach and potential revenue streams for HUTCHMED and its partner AstraZeneca.
-
Supported by Positive Clinical Data
The approval is supported by positive data from a pivotal Phase II registration study, which met its primary endpoint with an objective response rate of 32.3%.
Analysis · HCM · Life Sciences
This approval expands the market for ORPATHYS®, marking its third indication in China and establishing it as the first selective MET inhibitor for advanced gastric cancer with MET amplification. This addresses a significant unmet medical need in a large patient population and validates HUTCHMED's R&D capabilities, enhancing future revenue potential.
How filings like this one have moved
In the 30 days to Oct 20, 2026, 44.5% of the 283 measured filings Wiseek scored 9 moved their stock by 5% or more by the next session's close. The median move was -0.46%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, HCM was trading at $10.78 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.9B. The 52-week trading range was $9.77 to $19.50. This filing was assessed with positive market sentiment and an importance score of 9 out of 10.